Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Sep 26;9(3):7078.
doi: 10.4081/hr.2017.7078.

Safety and efficacy of ibrutinib in a patient with severe renal impairment

Kalman Filanovsky  1 , Lev Shvidel  1
Affiliations
Editorial

Safety and efficacy of ibrutinib in a patient with severe renal impairment

Kalman Filanovsky et al. Hematol Rep. .
No abstract available

Keywords: chronic renal failure; ibrutinib; lymphoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Rapidly improvement of renal function after the initiation of ibrutinib.
See this image and copyright information in PMC

References

    1. Castillo JJ, Treon SP, Davids MS. Inhibition of the bruton tyrosine kinase pathway in b-cell lymphoproliferative disorders. Cancer J 2016;22:34-9. - PubMed
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. - PubMed
    1. Stevens L, Viswanathan G, Weiner D. Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv Chronic Kidney Dis 2010;17:293-301. - PMC - PubMed
    1. Wang M, Blum K, Martin P, et al. Longterm follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739-45. - PMC - PubMed
    1. Imbruvica® (ibrutinib) capsules [prescribing information].. Sunnyvale, CA: Pharmacyclics; revised June 2016. Available from: https://www.janssenmd.com/pdf/imbruvica/PI-Imbruvica.pdf

Publication types

LinkOut - more resources